Pharmaceutical Development of a Parenteral Lyophilised Formulation of the Investigational Anticancer Agent ES-285.HCl

Monique W.J. Den Brok; Bastiaan Nuijen; Dieuwke M. Meijer; Elena Millán; Consuelo Manada; Jos H. Beijnen

Research ArticleRESEARCH

Pharmaceutical Development of a Parenteral Lyophilised Formulation of the Investigational Anticancer Agent ES-285.HCl

Monique W.J. Den Brok, Bastiaan Nuijen, Dieuwke M. Meijer, Elena Millán, Consuelo Manada and Jos H. Beijnen

PDA Journal of Pharmaceutical Science and Technology July 2005, 59 (4) 246-257;

Monique W.J. Den Brok

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: apmbk@slz.nl

Bastiaan Nuijen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dieuwke M. Meijer

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Elena Millán

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Consuelo Manada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jos H. Beijnen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
References
Info & Metrics
PDF

PreviousNext

In This Issue

PDA Journal of Pharmaceutical Science and Technology

Vol. 59, Issue 4

July/August 2005

Table of Contents
Index by Author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Pharmaceutical Development of a Parenteral Lyophilised Formulation of the Investigational Anticancer Agent ES-285.HCl

Message Subject (Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology

Message Body (Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 8 + 1 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Pharmaceutical Development of a Parenteral Lyophilised Formulation of the Investigational Anticancer Agent ES-285.HCl

Monique W.J. Den Brok, Bastiaan Nuijen, Dieuwke M. Meijer, Elena Millán, Consuelo Manada, Jos H. Beijnen

PDA Journal of Pharmaceutical Science and Technology Jul 2005, 59 (4) 246-257;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Pharmaceutical Development of a Parenteral Lyophilised Formulation of the Investigational Anticancer Agent ES-285.HCl

Monique W.J. Den Brok, Bastiaan Nuijen, Dieuwke M. Meijer, Elena Millán, Consuelo Manada, Jos H. Beijnen

PDA Journal of Pharmaceutical Science and Technology Jul 2005, 59 (4) 246-257;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
References
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Google Scholar

Main menu

User menu

Search

Pharmaceutical Development of a Parenteral Lyophilised Formulation of the Investigational Anticancer Agent ES-285.HCl

In This Issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Readers

Author/Reviewer Information

Parenteral Drug Association, Inc.